VBI Vaccines To Start Clinical Study Of Pan-Coronavirus Vaccine Candidate This Year

VBI Vaccines Inc VBIV announced updated clinical and preclinical data from its VBI-2900 coronavirus program, consisting of three candidates.

  • VBI-2902 and VBI-2905, evaluated at a low dose of 5µg, were well-tolerated in clinical studies, with no safety signals observed.
  • In the Phase 1b study (n=53), a single-dose booster of VBI-2905 increased neutralizing antibodies directed against the Beta variant 3.8-fold in participants who had previously received two doses of an mRNA vaccine (ancestral strain).
  • Approximately 2-fold increases were also seen in antibody levels against the ancestral and delta variant.
  • Against a panel of coronavirus variants in mice, reactivity was seen with VBI-2902 against all variants, including the ancestral strain, Delta, Beta, Omicron, Lambda, and RaTG13 (a bat coronavirus that is distant to circulating human strains).
  • In this same panel, VBI-2901 elicited an even stronger response against all variants tested.
  • VBI-2901 elicited a more significant difference in antibody levels from VBI-2902, ranging from 2.5-fold higher against the ancestral strain to 9.0-fold higher against the bat coronavirus.
  • Price Action: VBIV shares are down 1.66% at $1.78 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareSmall CapGeneralBriefsCOVID-19 CoronavirusCOVID-19 VaccinePhase 1 TrialPreclinical Phase
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!